• Increase font size
  • Default font size
  • Decrease font size
Home HPV and Men HPV and Men ACIP Recommends Routine Use of Gardasil with Males

ACIP Recommends Routine Use of Gardasil with Males

E-mail Print PDF

In late October the Advisory Committee on Immunization Practices (ACIP) approved a recommendation for routine use of the quadrivalent HPV vaccine with males 11-12 years of age.

HPV vaccines first came on the market in 2006 with the approval of Merck’s Gardasil®. In 2009 another HPV vaccine, GlaxoSmithKline’s Cervarix®, was also approved in the U.S. Gardasil® and Cervarix® both protect against persistent infections and diseases related to two “high risk” HPV types found in most cervical and anal cancers. Additionally, Gardasil® also protects against a pair of “low risk” HPV types found with about 90% of cases of genital warts.

In 2009 Gardasil® was approved for use in males to prevent genital warts, and ACIP issued a “permissive” recommendation that essentially left the decision of using the vaccine in boys and young men to the discretion of health care providers. The more robust recommendation to use Gardasil® “routinely” with boys ages 11-12 brings ACIP’s guidance in line with what it has previously issued for girls. ACIP recommends routine use of either Gardasil® or Cervarix® with females ages 11-12 year, with catch-up vaccination through age 26 for those who haven’t had the shots.

Speaking at a press briefing about the updated recommendations, CDC spokesperson Anne Schuchat, MD, said it makes sense to give HPV vaccines early: “It turns out that the age of 11 or 12 is a very good time to be vaccinated. Antibody or immune responses are the strongest and that's well before girls or boys would become sexually active. So the vaccine works most well when given at the younger age. We know parents are confused about when they ought to vaccinate their daughters and we hope to improve that messaging going forward.”